Every proxy submitted helps establish the quorum needed to conduct the Company's Annual Meeting, regardless of how shareholders choose to vote
SOLANA BEACH, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today reminds shareholders to vote their shares in advance of the Company's Annual Meeting of Shareholders, scheduled to be held virtually on July 17, 2026.
The Company is asking all shareholders of record, regardless of the number of shares owned, to participate by submitting their proxy as soon as possible.
Shareholders who have already voted are thanked for their participation. Those who have not yet voted are encouraged to do so as soon as possible using one of the methods described in the Company's proxy materials.
Importantly, submitting a proxy helps establish quorum regardless of how a shareholder chooses to vote. Whether a shareholder votes FOR, AGAINST, or ABSTAINS on any proposal, their participation helps the Company conduct its required business efficiently.
The Board of Directors has recommended votes on each of the proposals described in the proxy statement and encourages shareholders to review those materials carefully before casting their votes.
One of the requirements for conducting the Annual Meeting is achieving a quorum, meaning that a sufficient percentage of the Company's outstanding shares must be represented either through proxy submissions or virtual attendance. If a quorum is not achieved, the meeting may need to be adjourned and reconvened at a later date, resulting in additional expense and administrative effort for the Company.
Additional information regarding the Annual Meeting, including the Company's proxy statement and voting instructions, is available in the materials previously distributed to shareholders and filed with the U.S. Securities and Exchange Commission.
About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways, with a diversified pipeline addressing significant unmet needs in anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by an experienced executive team collaborating with world-class researchers and technology partners, Artelo applies rigorous scientific, regulatory, commercial, and treasury management practices, including digital assets, to maximize stakeholder value. More information is available at www.artelobio.com and X: @ArteloBio.